Vanda Pharmaceuticals Inc. announced that it has entered into a license agreement with UCSF, under which Vanda will acquire an exclusive worldwide license from UCSF to develop and commercialize a portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors. UCSF is eligible to receive up to $46 million in potential development, regulatory and sales milestones as well as single-digit tiered royalties on net sales should a product be successfully commercialized.
